8th International Congress Psoriasis from Gene to Clinic

The Queen Elizabeth II Conference Centre in London, UK, plays host to the 8^th International Congress Psoriasis from Gene to Clinic.

From the 30^th November to the 2^nd December, healthcare professionals are welcome to attend the extensive and varied scientific programme which covers sessions including:

• Genetic variation contributes to response to biologics: initial findings of the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium
• Targeting IL-17: Findings from recent clinical trials
• IL-23 inhibition as a strategy to treat immune-mediated inflammatory diseases
• Advances in genomic studies of psoriasis in China
• The evolution of T cell targeted therapy in psoriasis
• The lymphatic system plays an important role in the migration of pathogenic T-cells towards synovial joints and entheses in psoriasis
• Quality of care and use of systemic drugs for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany

The co-chairs are Jonathan Barker and Christopher Griffiths, and the local organising committee consists of David Burden, Catherine Smith and Richard Warren.

The scientific committee is made up of:

• Hervé Bachelez – Paris, France
• James Elder – Ann Arbor, USA
• Michel Gilliet – Lausanne, Switzerland
• Lars Iversen – Aarhus, Denmark
• Alexa Kimball – Boston, USA
• James Krueger – New York, USA
• Alan Menter – Dallas, USA
• Errol Prens – Rotterdam, The Netherlands
• Jörg Prinz – Munich, Germany
• Peter Van de Kerkhof – Nijmegen, The Netherlands

Message from the organisers on the event website:

“Considerable progress has been made over recent years in our understanding of psoriasis at both fundamental basic science and clinical levels. Identification of immunopathological mechanisms that lead to the expression of disease and elucidation of cellular processes which control proliferation and differentiation are integral to the development of new therapies and therapeutic approaches specifically designed for psoriasis. Furthermore, significant progress has been made in understanding the genetic architecture of psoriasis which in turn highlight key biological pathways, some shared with other auto-immune diseases. Emerging evidence suggests that psoriasis is associated with risk of cardiovascular disease and other comorbidities. The true relationships between these conditions and determination of mechanisms will be important in the long-term management of psoriasis.

Building on the success of our previous International Congresses held every three years since 1996, Psoriasis: from Gene to Clinic is designed to provide a forum for experts from around the world to present and discuss cutting edge issues. Delegates are anticipated to include clinicians, scientists and members of the biotechnology and pharmaceutical industries.

To reflect the areas of current scientific and clinical interests, the meeting will concentrate on specific plenary topics: genes and pathogenesis; inflammation and immunity, comorbidities and targeted therapeutics.

There will be plenty of opportunity for free communications on any aspect of psoriasis, either as oral or poster presentations. Time will be available for informal discussions. The high quality of the meeting is again reflected in our choice of venue. The Queen Elizabeth II Conference Centre is uniquely situated in the shadow of Big Ben, Westminster Abbey and the London Eye. The welcome reception will take place at the conference centre and the Congress Banquet will be held at the magnificent Natural History Museum, a unique, historic venue in the heart of London.”